Business
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
PALO ALTO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical
About this update from Bridgebio Pharma, Inc.
[{"type":"text","content":"PALO ALTO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire abstract and two moderated ePosters on the clinical outcomes and quality of life measures provided by acoramidis in variant transthyretin amyloid cardiomyopathy (ATTR-CM) and one moderated ePoster on a post-hoc analysis of the lower incidence rate of atrial fibrillation-related events in patients with ATTR-CM, all from the ATTRibute-CM study will be shared at the Annual Congress of the Heart Failure Association of the ESC (Heart Failure 2025), taking place in Belgrade, Serbia on May 17 - 20, 2025. In addition to the four abstracts, three moderated ePosters will be shared on the disease progression of ATTR-CM in a real-world setting, a retrospective cohort study on manifestation to diagnosis of ATTR-CM, and data on the cause of death of ATTR-CM patients in the ATTRibute-CM study. Rapid-fire Abstract Acoramidis Improves Serum TTR Levels in Patients with Wild-type or Variant Transthyretin Amyloid Cardiomyopathy: Results from ATTRibute-CMPresenter: Anique Ducharme, M.D., Université de Montréal, CANDate: Tuesday, May 20 at 8:30 am CEST/2:30 am ET Moderated ePosters: Effect of Acoramidis on Functional Capacity and Quality of Life in Patients with Variant ATTR-CM: Results from ATTRibute-CMPresenter: Marianna Fontana, M.D., University College London, UKDate: Sunday, May 18 at 11:00 am CEST/5:00 am ET Effect of Acoramidis on All-cause Mortality, Cardiovascular Hospitalization and NT-proBNP in Variant ATTR-CM: Results from ATTRibute-CMPresenter: Marianna Fontana, M.D., University College London, UKDate: Sunday, May 18 at 11:00 am CEST/5:00 am ET Acoramidis Treatment Is Associated with a Lower Incidence of Atrial Fibrillation-related Events in Patients with ATTR-CM: A Post Hoc Analysis of the ATTRibute-CM trialPresenter: Kevin Alexander, M.D., Stanford University School of Medicine, USADate: Sunday, May 18 at 11:00 am CEST/5:00 am ET Disease Progression Among Patients Receiving Tafamidis for ATTR-CM in a Real-world SettingPresenter: Daniel P. Judge, M.D., Medical University of South Carolina, USA Date: Sunday, May 18 at 11:00 am CEST/5:00 am ET Cause of Death in Patients with Transthyretin Amyloid Cardiomyopathy (ATT...